Novelty Nobility Inc. is a private clinical stage biotech company located in Pangyo, South Korea, and Boston, Massachusetts. Founded in 2017, the company is focused on the research of novel angiogenesis targets and developing antibody-based therapeutics in ophthalmology and oncology. Their slogan, "Novel Science, Noble Management," embodies their commitment to innovative science and ethical management.
Recently, on 13 May 2022, the company secured a significant KRW34.10B Series B investment from a consortium of investors including KB Investments, Mirae Asset Venture Investment, HB Investment, K2 Investment Partners, BSK Investment, SGI Venture Capital, and SL Investment.
As Novelty Nobility Inc. continues to make strides in the fields of biotechnology and healthcare, its unique approach and strong investor backing position it as a promising player in the global biotech industry.
No recent news or press coverage available for Novelty Nobility Inc..